Jeremy Schmidt
Family · New Braunfels, TXNPI 1184892622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,593 of the $132,479 with a category attached, or 69.9%. 60 manufacturers reported payments, led by Novo Nordisk at 55.1% of the total. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $122.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$73K
- Lilly USA, LLC$40K
- Mannkind Corporation$5K
- Abbott$3K
- Zealand Pharma US, Inc.$2K
- Dexcom, Inc.$828
- plus $8K from 54 others
What the payments were for
- Consulting fees$1,0951%
- Speaking & faculty fees$92,59370%
- Travel & lodging$18,14614%
- Food & beverage$20,54516%
- Education$400%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,479 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 527 | $740,823 |
| JardianceEmpagliflozin | 160 | $194,346 |
| MounjaroTirzepatide | 146 | $181,840 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $85,687 |
| TrulicityDulaglutide | 53 | $76,913 |
| FarxigaDapagliflozin Propanediol | 74 | $67,749 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $64,112 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $42,534 |
| FiaspInsulin Aspart (Niacinamide) | 33 | $39,200 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $37,194 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $28,644 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $27,241 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 33 | $25,813 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $23,191 |
| SynjardyEmpagliflozin/Metformin Hcl | 17 | $22,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $73,046 | $793,878596 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $40,093 | $265,927221 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $701 | $254,239218 claims |
| AstraZenecaFarxiga | $725 | $67,74974 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $320 | $2,835201 claims |
| AbbVieSynthroid | $21 | $2,02036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in New Braunfels
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.